CTLA4 and hereditary sensory and autonomic neuropathy: A meta-analysis revealed that the incidence of CIP was 1.6% with anti-PD-1 monotherapy vs. 6.6% with the anti-PD-1/CTLA-4 combination, indicating a greater CIP risk with dual vs. single ICI therapy (9).